Furthermore, high ZDHHC15 expression was significantly associated with worse prognosis in patients with IDH1 wild-type and mutant glioma, 1p/19q non-codeletion glioma, MGMT promoter methylated and non-methylated glioma, and primary and recurrent glioma (Figure S8C-F). This evidence concerns the gene MGMT and glioma.